NASDAQ:INSY

INSYS Therapeutics Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.23
MA: $23,687,640.18
$65,799,000.00
52-Week Range N/A
VolumeN/A
Average Volume9.52 million shs
Market Capitalization$21.71 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21

Competitors

INSYS Therapeutics (NASDAQ:INSY) Vs. COCP, REPH, ASRT, VBLT, PRPH, and CLSN

Should you be buying INSY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to INSYS Therapeutics, including Cocrystal Pharma (COCP), Recro Pharma (REPH), Assertio (ASRT), Vascular Biogenics (VBLT), ProPhase Labs (PRPH), and Celsion (CLSN).

Cocrystal Pharma (NASDAQ:COCP) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cocrystal Pharma and INSYS Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cocrystal Pharma00203.00
INSYS Therapeutics0000N/A

Cocrystal Pharma presently has a consensus price target of $4.75, suggesting a potential upside of 295.83%.

Valuation and Earnings

This table compares Cocrystal Pharma and INSYS Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cocrystal Pharma$6.56 million13.07$-48,170,000.00($0.06)-20.00
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A

Cocrystal Pharma has higher earnings, but lower revenue than INSYS Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cocrystal Pharma and INSYS Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cocrystal Pharma-2,938.09%-25.81%-23.98%
INSYS Therapeutics-346.61%-1,430.37%-64.04%

Volatility & Risk

Cocrystal Pharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500.

Institutional and Insider Ownership

18.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are owned by institutional investors. 10.8% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 65.4% of INSYS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cocrystal Pharma beats INSYS Therapeutics on 6 of the 11 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Comparatively, 65.4% of INSYS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Recro Pharma and INSYS Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recro Pharma00203.00
INSYS Therapeutics0000N/A

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%.

Volatility & Risk

Recro Pharma has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500.

Valuation & Earnings

This table compares Recro Pharma and INSYS Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A

Recro Pharma has higher revenue and earnings than INSYS Therapeutics. INSYS Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recro Pharma and INSYS Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recro Pharma-34.14%N/A-18.97%
INSYS Therapeutics-346.61%-1,430.37%-64.04%

Summary

Recro Pharma beats INSYS Therapeutics on 9 of the 11 factors compared between the two stocks.

INSYS Therapeutics (NASDAQ:INSY) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares INSYS Therapeutics and Assertio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A
Assertio$229.50 million0.37$-217,200,000.00($3.07)-0.16

INSYS Therapeutics has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 40.0% of Assertio shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Comparatively, 2.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for INSYS Therapeutics and Assertio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INSYS Therapeutics0000N/A
Assertio00403.00

Assertio has a consensus target price of $3.50, suggesting a potential upside of 623.44%.

Profitability

This table compares INSYS Therapeutics and Assertio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INSYS Therapeutics-346.61%-1,430.37%-64.04%
Assertio-145.15%-259.36%-55.13%

Risk & Volatility

INSYS Therapeutics has a beta of 3.21, meaning that its stock price is 221% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Assertio beats INSYS Therapeutics on 7 of the 11 factors compared between the two stocks.

INSYS Therapeutics (NASDAQ:INSY) and Vascular Biogenics (NASDAQ:VBLT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares INSYS Therapeutics and Vascular Biogenics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A
Vascular Biogenics$560,000.00145.42$-19,460,000.00($0.54)-3.13

Vascular Biogenics has lower revenue, but higher earnings than INSYS Therapeutics. Vascular Biogenics is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Vascular Biogenics shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for INSYS Therapeutics and Vascular Biogenics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INSYS Therapeutics0000N/A
Vascular Biogenics00403.00

Vascular Biogenics has a consensus target price of $4.1250, suggesting a potential upside of 144.08%.

Profitability

This table compares INSYS Therapeutics and Vascular Biogenics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INSYS Therapeutics-346.61%-1,430.37%-64.04%
Vascular Biogenics-2,692.41%-61.77%-47.23%

Risk & Volatility

INSYS Therapeutics has a beta of 3.21, meaning that its stock price is 221% more volatile than the S&P 500. Comparatively, Vascular Biogenics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Summary

INSYS Therapeutics beats Vascular Biogenics on 6 of the 11 factors compared between the two stocks.

INSYS Therapeutics (NASDAQ:INSY) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares INSYS Therapeutics and ProPhase Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A
ProPhase Labs$9.88 million8.24$-3,150,000.00N/AN/A

ProPhase Labs has lower revenue, but higher earnings than INSYS Therapeutics.

Volatility & Risk

INSYS Therapeutics has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for INSYS Therapeutics and ProPhase Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INSYS Therapeutics0000N/A
ProPhase Labs00103.00

ProPhase Labs has a consensus price target of $25.00, indicating a potential upside of 365.55%.

Profitability

This table compares INSYS Therapeutics and ProPhase Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INSYS Therapeutics-346.61%-1,430.37%-64.04%
ProPhase Labs-12.92%-15.95%-11.65%

Institutional and Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ProPhase Labs shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Comparatively, 29.2% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ProPhase Labs beats INSYS Therapeutics on 5 of the 9 factors compared between the two stocks.

Celsion (NASDAQ:CLSN) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Celsion and INSYS Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
INSYS Therapeutics-346.61%-1,430.37%-64.04%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Celsion and INSYS Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
INSYS Therapeutics0000N/A

Celsion presently has a consensus price target of $4.00, indicating a potential upside of 277.36%.

Institutional & Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are owned by institutional investors. 20.5% of Celsion shares are owned by insiders. Comparatively, 65.4% of INSYS Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Celsion and INSYS Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00159.04$-16,850,000.00($0.91)-1.16
INSYS Therapeutics$82.08 million0.00$-124,510,000.00($1.39)N/A

Celsion has higher earnings, but lower revenue than INSYS Therapeutics. Celsion is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Celsion has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500.

Summary

INSYS Therapeutics beats Celsion on 6 of the 10 factors compared between the two stocks.


INSYS Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cocrystal Pharma logo
COCP
Cocrystal Pharma
1.4$1.20flat$85.76 million$6.56 million-0.72Gap Up
Recro Pharma logo
REPH
Recro Pharma
1.8$2.76flat$85.60 million$99.22 million13.80Gap Up
Assertio logo
ASRT
Assertio
1.6$0.48flat$83.95 million$229.50 million-0.19Gap Up
Vascular Biogenics logo
VBLT
Vascular Biogenics
1.3$1.69flat$81.44 million$560,000.00-2.96
ProPhase Labs logo
PRPH
ProPhase Labs
1.1$5.37flat$81.38 million$9.88 million0.00Analyst Downgrade
Celsion logo
CLSN
Celsion
1.3$1.06flat$79.52 million$500,000.00-1.47Analyst Upgrade
Gap Up
Galmed Pharmaceuticals logo
GLMD
Galmed Pharmaceuticals
1.5$3.07flat$77.01 million$2.04 million-2.44Increase in Short Interest
News Coverage
Avenue Therapeutics logo
ATXI
Avenue Therapeutics
1.2$4.54flat$76.04 millionN/A-7.96
Acasti Pharma logo
ACST
Acasti Pharma
1.2$0.41flat$73.06 millionN/A-3.70Gap Up
Chembio Diagnostics logo
CEMI
Chembio Diagnostics
1.3$3.61flat$72.86 million$34.46 million-2.96
Diffusion Pharmaceuticals logo
DFFN
Diffusion Pharmaceuticals
1.1$0.71flat$72.05 millionN/A-0.40Gap Up
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
1.4$1.42flat$71.72 millionN/A-1.22
Entasis Therapeutics logo
ETTX
Entasis Therapeutics
1.5$1.90flat$70.89 million$7 million-0.57Decrease in Short Interest
CohBar logo
CWBR
CohBar
1.5$1.13flat$69.82 millionN/A-3.32Gap Down
Vaccinex logo
VCNX
Vaccinex
1.5$2.41flat$68.54 million$520,000.00-1.45
EDSA
Edesa Biotech
0.9$5.14flat$67.74 million$330,000.00-6.95
Purple Biotech logo
PPBT
Purple Biotech
0.6$3.86flat$67.59 million$1 million-1.29
Monopar Therapeutics logo
MNPR
Monopar Therapeutics
1.5$5.31flat$66.73 millionN/A-8.30
Daré Bioscience logo
DARE
Daré Bioscience
1.4$1.40flat$66.24 millionN/A-1.56
NeuroBo Pharmaceuticals logo
NRBO
NeuroBo Pharmaceuticals
1.7$3.23flat$63.54 millionN/A-0.79Earnings Announcement
News Coverage
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.2$5.64flat$63.33 million$1.02 million-2.27
Stealth BioTherapeutics logo
MITO
Stealth BioTherapeutics
1.4$1.12flat$62.09 million$21.09 million28.01
AzurRx BioPharma logo
AZRX
AzurRx BioPharma
1.4$0.79flat$59.11 millionN/A0.00
Neos Therapeutics logo
NEOS
Neos Therapeutics
0.7$1.15flat$57.22 million$64.65 million-2.61High Trading Volume
Aerpio Pharmaceuticals logo
ARPO
Aerpio Pharmaceuticals
1.2$1.20flat$56.78 million$20.16 million-12.00Decrease in Short Interest
Advaxis logo
ADXS
Advaxis
0.6$0.47flat$56.46 million$20.88 million-0.96Gap Up
Alimera Sciences logo
ALIM
Alimera Sciences
1.3$9.80flat$56.38 million$53.94 million-12.40
AgeX Therapeutics logo
AGE
AgeX Therapeutics
0.5$1.47flat$55.76 million$1.73 million-4.90
Aeterna Zentaris logo
AEZS
Aeterna Zentaris
0.6$0.88flat$55.16 million$530,000.00-4.89Gap Up
Pulmatrix logo
PULM
Pulmatrix
1.3$0.97flat$54.56 million$7.91 million-1.28
Timber Pharmaceuticals logo
TMBR
Timber Pharmaceuticals
1.0$1.47flat$54.16 million$60,000.000.00Gap Up
Evoke Pharma logo
EVOK
Evoke Pharma
1.4$1.65flat$53.41 millionN/A-3.37Increase in Short Interest
Catabasis Pharmaceuticals logo
CATB
Catabasis Pharmaceuticals
1.6$2.24flat$52.45 millionN/A-1.05
Soligenix logo
SNGX
Soligenix
1.4$1.31flat$52.43 million$4.60 million-2.11
Rezolute logo
RZLT
Rezolute
0.6$6.20flat$51.78 millionN/A0.00Increase in Short Interest
Gap Down
CNS Pharmaceuticals logo
CNSP
CNS Pharmaceuticals
1.4$2.08flat$51.61 millionN/A-7.43Decrease in Short Interest
News Coverage
Salarius Pharmaceuticals logo
SLRX
Salarius Pharmaceuticals
1.5$1.15flat$51.44 million$3.46 million-0.54Analyst Upgrade
Increase in Short Interest
News Coverage
Gap Up
Ocuphire Pharma logo
OCUP
Ocuphire Pharma
1.9$4.58flat$50.06 millionN/A0.00
Forward Pharma A/S logo
FWP
Forward Pharma A/S
0.7$7.09flat$48.15 millionN/A0.00Upcoming Earnings
Trevi Therapeutics logo
TRVI
Trevi Therapeutics
1.7$2.40flat$47.79 millionN/A-1.61
Cyclacel Pharmaceuticals logo
CYCC
Cyclacel Pharmaceuticals
1.4$6.52flat$46.32 million$150,000.00-1.22
GHSI
Guardion Health Sciences
0.5$1.84flat$44.95 million$900,000.000.00Gap Up
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.99flat$44.61 million$47.53 million-13.59
Kintara Therapeutics logo
KTRA
Kintara Therapeutics
1.8$1.39flat$42.57 millionN/A-0.70Decrease in Short Interest
Gap Up
Panbela Therapeutics logo
PBLA
Panbela Therapeutics
1.7$4.20flat$42.35 millionN/A0.00Gap Down
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
1.8$4.46flat$42.33 millionN/A-1.34
Qualigen Therapeutics logo
QLGN
Qualigen Therapeutics
1.1$1.82flat$41.97 millionN/A-0.36
RVPH
Reviva Pharmaceuticals
0.2$4.41flat$40.71 millionN/A-9.59Gap Up
Auris Medical logo
EARS
Auris Medical
0.5$3.50flat$39.96 millionN/A-1.52Decrease in Short Interest
Acer Therapeutics logo
ACER
Acer Therapeutics
1.3$2.72flat$38.92 millionN/A-1.31
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.